Nimodipine in human alcohol withdrawal syndrome - an open study

A. C. Altamura, M. G. Regazzetti, M. Porta

Research output: Contribution to journalArticle

Abstract

The aim of this study was to evaluate the efficacy and tolerability of the DHP Ca2+ antagonist nimodipine in human AWS and post-AWS. Ten hospitalized alcoholics of both sexes with a diagnosis of AWS according to the DSM-III criteria were treated for 3 weeks in monotherapy with nimodipine p.o. at flexible daily dosages. Evaluation of AWS symptoms was performed at baseline and after 3, 5, 7, 10, 14 and 21 days. A statistically significant improvement of AWS was seen at evaluation on day 3, particularly in neurovegetative and psychopathological symptoms, and lasted up to the end of the study. The treatment was well tolerated and no side effects were observed or reported. In this pilot, open study nimodipine proved effective in the treatment of mild-to-moderate AWS. If these data are comfirmed in a double-blind study nimodipine could be a rational alternative to benzodiazepines in the treatment of AWS.

Original languageEnglish
Pages (from-to)37-40
Number of pages4
JournalEuropean Neuropsychopharmacology
Volume1
Issue number1
DOIs
Publication statusPublished - 1990

Fingerprint

Nimodipine
Alcohols
Symptom Assessment
Alcoholics
Benzodiazepines
Double-Blind Method
Diagnostic and Statistical Manual of Mental Disorders
Therapeutics

Keywords

  • Alcohol
  • Alcohol withdrawal syndrome
  • Nimodipine
  • Withdrawal

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health
  • Biological Psychiatry
  • Neurology
  • Pharmacology
  • Psychology(all)

Cite this

Nimodipine in human alcohol withdrawal syndrome - an open study. / Altamura, A. C.; Regazzetti, M. G.; Porta, M.

In: European Neuropsychopharmacology, Vol. 1, No. 1, 1990, p. 37-40.

Research output: Contribution to journalArticle

@article{e8e4b373854d435492558a37319d9099,
title = "Nimodipine in human alcohol withdrawal syndrome - an open study",
abstract = "The aim of this study was to evaluate the efficacy and tolerability of the DHP Ca2+ antagonist nimodipine in human AWS and post-AWS. Ten hospitalized alcoholics of both sexes with a diagnosis of AWS according to the DSM-III criteria were treated for 3 weeks in monotherapy with nimodipine p.o. at flexible daily dosages. Evaluation of AWS symptoms was performed at baseline and after 3, 5, 7, 10, 14 and 21 days. A statistically significant improvement of AWS was seen at evaluation on day 3, particularly in neurovegetative and psychopathological symptoms, and lasted up to the end of the study. The treatment was well tolerated and no side effects were observed or reported. In this pilot, open study nimodipine proved effective in the treatment of mild-to-moderate AWS. If these data are comfirmed in a double-blind study nimodipine could be a rational alternative to benzodiazepines in the treatment of AWS.",
keywords = "Alcohol, Alcohol withdrawal syndrome, Nimodipine, Withdrawal",
author = "Altamura, {A. C.} and Regazzetti, {M. G.} and M. Porta",
year = "1990",
doi = "10.1016/0924-977X(90)90008-X",
language = "English",
volume = "1",
pages = "37--40",
journal = "European Neuropsychopharmacology",
issn = "0924-977X",
publisher = "Elsevier Science B.V.",
number = "1",

}

TY - JOUR

T1 - Nimodipine in human alcohol withdrawal syndrome - an open study

AU - Altamura, A. C.

AU - Regazzetti, M. G.

AU - Porta, M.

PY - 1990

Y1 - 1990

N2 - The aim of this study was to evaluate the efficacy and tolerability of the DHP Ca2+ antagonist nimodipine in human AWS and post-AWS. Ten hospitalized alcoholics of both sexes with a diagnosis of AWS according to the DSM-III criteria were treated for 3 weeks in monotherapy with nimodipine p.o. at flexible daily dosages. Evaluation of AWS symptoms was performed at baseline and after 3, 5, 7, 10, 14 and 21 days. A statistically significant improvement of AWS was seen at evaluation on day 3, particularly in neurovegetative and psychopathological symptoms, and lasted up to the end of the study. The treatment was well tolerated and no side effects were observed or reported. In this pilot, open study nimodipine proved effective in the treatment of mild-to-moderate AWS. If these data are comfirmed in a double-blind study nimodipine could be a rational alternative to benzodiazepines in the treatment of AWS.

AB - The aim of this study was to evaluate the efficacy and tolerability of the DHP Ca2+ antagonist nimodipine in human AWS and post-AWS. Ten hospitalized alcoholics of both sexes with a diagnosis of AWS according to the DSM-III criteria were treated for 3 weeks in monotherapy with nimodipine p.o. at flexible daily dosages. Evaluation of AWS symptoms was performed at baseline and after 3, 5, 7, 10, 14 and 21 days. A statistically significant improvement of AWS was seen at evaluation on day 3, particularly in neurovegetative and psychopathological symptoms, and lasted up to the end of the study. The treatment was well tolerated and no side effects were observed or reported. In this pilot, open study nimodipine proved effective in the treatment of mild-to-moderate AWS. If these data are comfirmed in a double-blind study nimodipine could be a rational alternative to benzodiazepines in the treatment of AWS.

KW - Alcohol

KW - Alcohol withdrawal syndrome

KW - Nimodipine

KW - Withdrawal

UR - http://www.scopus.com/inward/record.url?scp=0025509238&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025509238&partnerID=8YFLogxK

U2 - 10.1016/0924-977X(90)90008-X

DO - 10.1016/0924-977X(90)90008-X

M3 - Article

C2 - 2136211

AN - SCOPUS:0025509238

VL - 1

SP - 37

EP - 40

JO - European Neuropsychopharmacology

JF - European Neuropsychopharmacology

SN - 0924-977X

IS - 1

ER -